 Connection
Michael DiStefano to Humans
This is a "connection" page, showing publications Michael DiStefano has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.444 |
|
|
|
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 Mar; 24(2):261-269.
Score: 0.024
-
DiStefano MJ, Chen NC, Asche CV, Anderson KE, Mattingly TJ. "The crux of the community": A qualitative focus group study of the impact of community pharmacy closures in Colorado and Utah. J Am Pharm Assoc (2003). 2026 Jan-Feb; 66(1):102940.
Score: 0.024
-
Charlton V, DiStefano MJ. The ethical canary: narrow reflective equilibrium as a source of moral justification in healthcare priority-setting. J Med Ethics. 2024 Dec 23; 50(12):835-840.
Score: 0.022
-
DiStefano MJ, McQueen RB, Gao V, Klein MP, Snell-Bergeon JK, Polsky S. The Cost of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 1 Diabetes Pregnancies in the United States: A Cost-Consequences Analysis Using Real-World Evidence. Diabetes Technol Ther. 2025 Apr; 27(4):329-333.
Score: 0.022
-
Markell J, Odouard I, Anderson GF, DiStefano MJ. Consumer Perceptions of Safety Information in Direct-to-Consumer Print Advertisements for Alzheimer Drugs. JAMA Netw Open. 2024 08 01; 7(8):e2431110.
Score: 0.022
-
DiStefano MJ, Pearson SD, Rind DM, Zemplenyi A. How Do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study. Value Health. 2024 08; 27(8):1066-1072.
Score: 0.021
-
Charlton V, DiStefano M. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification. BMC Med Ethics. 2024 03 06; 25(1):28.
Score: 0.021
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.021
-
DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
Score: 0.021
-
DiStefano MJ, Levy JF, Odouard IC, Anderson GF. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations. Value Health. 2023 11; 26(11):1618-1624.
Score: 0.021
-
DiStefano MJ, Karim SA, Krubiner CB, Hofman KJ. Integrating Health Technology Assessment and the Right to Health in South Africa: A Qualitative Content Analysis of Substantive Values in Landmark Judicial Decisions. J Law Med Ethics. 2023; 51(1):131-149.
Score: 0.020
-
DiStefano MJ, Kang SY, Parasrampuria S, Anderson GF. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. JAMA Health Forum. 2023 05 05; 4(5):e231090.
Score: 0.020
-
DiStefano MJ. Moral and Social Values in Evidence-Informed Deliberative Processes for Health Benefit Package Design Comment on "Evidence-Informed Deliberative Processes for Health Benefit Package Design - Part II: A Practical Guide". Int J Health Policy Manag. 2023; 12:7480.
Score: 0.020
-
DiStefano MJ, Abdool Karim S, Krubiner CB. Integrating health technology assessment and the right to health: a qualitative content analysis of procedural values in South African judicial decisions. Health Policy Plan. 2022 May 12; 37(5):644-654.
Score: 0.019
-
DiStefano MJ, Alexander GC, Anderson GF. Reply to: The informed majority could help make research into Alzheimer's disease fairer and more efficient. J Am Geriatr Soc. 2022 06; 70(6):1883-1885.
Score: 0.019
-
DiStefano MJ, Alexander GC, Polsky D, Anderson GF. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey. J Am Geriatr Soc. 2022 06; 70(6):1685-1694.
Score: 0.018
-
DiStefano MJ, Kang SY, Yehia F, Morales C, Anderson GF. Assessing the Added Therapeutic Benefit of Ultra-Expensive Drugs. Value Health. 2021 03; 24(3):397-403.
Score: 0.017
-
DiStefano MJ, Rivera YM, Thrul J, Ali J. Promoting Justice in Locating and Tracking Research Participants Through Social Media. Am J Bioeth. 2019 06; 19(6):71-73.
Score: 0.015
-
DiStefano MJ. Wearable Biometric Technologies and Public Health. Am J Bioeth. 2017 01; 17(1):79-81.
Score: 0.013
-
Socal MP, Kandula NR, Bareamichael PI, Ballreich J, Odouard I, Kang SY, Acha JO, Anderson KE, DiStefano M, Gerchman F, Levy JF. Improving Affordability of Pharmaceutical Treatments for Diabetes: A Call for Action. Diabetes Care. 2026 Jan 01; 49(1):30-43.
Score: 0.006
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.
Score: 0.006
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
Score: 0.006
-
Nikitin D, Mustafa RA, McQueen B, Zemplenyi A, DiStefano MJ, Nhan E, Kayali Y, Richardson M, Rind DM, Pearson SD, Agboola F. The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder. J Manag Care Spec Pharm. 2024 Oct; 30(10):1191-1195.
Score: 0.006
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
Score: 0.005
-
Charlton V, DiStefano M, Mitchell P, Morrell L, Rand L, Badano G, Baker R, Calnan M, Chalkidou K, Culyer A, Howdon D, Hughes D, Lomas J, Max C, McCabe C, O'Mahony JF, Paulden M, Pemberton-Whiteley Z, Rid A, Scuffham P, Sculpher M, Shah K, Weale A, Wester G. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment. Health Econ Policy Law. 2024 04; 19(2):153-173.
Score: 0.005
-
Anderson KE, DiStefano MJ, Liu A, Mattingly TJ, Socal MP, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs. Value Health. 2023 09; 26(9):1381-1388.
Score: 0.005
-
Krubiner CB, Tugendhaft A, DiStefano MJ, Barsdorf NW, Merritt MW, Goldstein SJ, Mosam A, Potgieter S, Hofman KJ, Faden RR. The Value of Explicit, Deliberative, and Context-Specified Ethics Analysis for Health Technology Assessment: Evidence From a Novel Approach Piloted in South Africa. Value Health Reg Issues. 2023 Mar; 34:23-30.
Score: 0.005
-
Krubiner CB, Barsdorf NW, Goldstein SJ, Mosam A, Potgieter S, DiStefano MJ, Tugendhaft A, Merritt MW, Li R, Chalkidou K, Faden RR, Hofman KJ. Developing and piloting a context-specified ethics framework for health technology assessment: the South African Values and Ethics for Universal Health Coverage approach. Int J Technol Assess Health Care. 2022 Mar 08; 38(1):e26.
Score: 0.005
-
Kang SY, DiStefano MJ, Yehia F, Koszalka MV, Padula WV. Critical Care Beds With Continuous Lateral Rotation Therapy to Prevent Ventilator-Associated Pneumonia and Hospital-Acquired Pressure Injury: A Cost-effectiveness Analysis. J Patient Saf. 2021 03 01; 17(2):149-155.
Score: 0.004
-
Kang SY, Bai G, DiStefano MJ, Socal MP, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. Annu Rev Public Health. 2020 04 02; 41:499-512.
Score: 0.004
-
Kang SY, DiStefano MJ, Socal MP, Anderson GF. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries. Health Aff (Millwood). 2019 05; 38(5):804-811.
Score: 0.004
-
Ali J, DiStefano MJ, Coates McCall I, Gibson DG, Al Kibria GM, Pariyo GW, Labrique AB, Hyder AA. Ethics of mobile phone surveys to monitor non-communicable disease risk factors in low- and middle-income countries: A global stakeholder survey. Glob Public Health. 2019 08; 14(8):1167-1181.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|